Dyne Therapeutics, Inc. (DYN)
DYN moved a median of +0.14% 30 minutes after news, and +0.33% by the close. How DYN actually reacts to news — the realized, point-in-time move the market made, measured across 855 labeled events over the last three years with zero look-ahead.
DYN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 52% | 855 |
| 30-min | +0.14% | 52% | 855 |
| 60-min | +0.25% | 53% | 855 |
| to close | +0.33% | 53% | 850 |
| Middle 50% of DYN reactions | -0.99% to +1.82% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 855 |
Half of all Dyne Therapeutics, Inc. news events land between -0.99% and +1.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DYN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | 0.00% | 41% | +0.31% |
| Analyst downgrades | 14 | +0.04% | 50% | -0.72% |
| Coverage initiations | 37 | -1.07% | 27% | -0.47% |
| Rating reiterations | 109 | -0.23% | 39% | -0.26% |
| Price-target raises | 17 | -0.15% | 47% | -0.02% |
| Price-target cuts | 15 | +0.05% | 60% | -0.34% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how DYN ranks against every other measured name →
That’s how DYN usually reacts — get an email when it moves on news →Email me when DYN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DYN's baseline. Nothing else.
Recent DYN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | Press release | GlobeNewswire | +3.08% | +0.37% | |
| Form 8-K Dyne Therapeutics, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | +0.37% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.22% | -5.31% | |
| Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings | Press release | GlobeNewswire | +7.00% | +19.40% | |
| Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting | Press release | GlobeNewswire | -1.07% | -1.23% | |
| Dyne Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.09% | -1.60% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.23% | -0.50% | |
| Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +1.14% | +5.02% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.14% | +5.02% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | +5.02% | |
| Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) | Press release | GlobeNewswire | +1.18% | +1.89% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.12% | +2.52% | |
| Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.48% | +2.17% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +1.37% | +4.10% | |
| Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock | Press release | GlobeNewswire | +2.17% | +5.12% | |
| Dyne Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | +2.17% | +5.12% | |
| Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | Press release | GlobeNewswire | -2.69% | -4.52% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -2.69% | -4.52% | |
| Dyne Therapeutics Appoints Barry Greene to Board of Directors | Press release | GlobeNewswire | +2.57% | -0.93% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.57% | -0.93% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.83% | +3.68% | |
| Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | Press release | GlobeNewswire | +0.16% | +4.75% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +4.75% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | +4.43% | |
| Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | Press release | GlobeNewswire | +0.78% | +4.29% | |
| Form 8-K Dyne Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.78% | +4.29% | |
| Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | Press release | GlobeNewswire | -0.86% | +0.67% | |
| Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | Press release | GlobeNewswire | +3.65% | +8.53% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.06% | +1.22% | |
| Dyne Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.27% | +0.44% | |
| Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +3.33% | +5.13% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.33% | +5.13% | |
| Form 8-K Dyne Therapeutics, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.33% | +5.13% | |
| Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting | Press release | GlobeNewswire | +4.71% | +0.67% | |
| Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.05% | -3.90% | |
| Form ARS Dyne Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.05% | -3.90% | |
| Form DEF 14A Dyne Therapeutics, Inc. For: Apr 22 | SEC filing · Form DEF | SEC EDGAR | +0.05% | -3.90% | |
| Form DEFA14A Dyne Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.05% | -3.90% | |
| Form PRE 14A Dyne Therapeutics, Inc. For: Apr 09 | SEC filing · Form PRE | SEC EDGAR | +1.42% | -5.08% | |
| Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines | Press release | GlobeNewswire | +1.17% | -1.74% | |
| Form S-8 Dyne Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.29% | -0.76% | |
| Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | Press release | GlobeNewswire | +3.80% | +15.85% | |
| Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | Press release | GlobeNewswire | +3.80% | +15.85% | |
| Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +2.30% | +9.27% | |
| Form 10-K Dyne Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.30% | +9.27% | |
| Form 8-K Dyne Therapeutics, Inc. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | +9.27% | |
| Form S-8 Dyne Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.30% | +9.27% | |
| Dyne Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +2.32% | +3.81% | |
| Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference | Press release | GlobeNewswire | +0.13% | +3.14% | |
| Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | Press release | GlobeNewswire | -0.92% | +1.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DYN section they belong to.
Where else DYN is measured.
DYN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dyne Therapeutics, Inc.'s median reaction calculated?
Every labeled DYN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 855 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of DYN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DYN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.